In the above-named article by Nölting S, Bechmann N, Taieb D, Beuschlein F, Fassnacht M, Kroiss M, Eisenhofer G, Grossman A, and Pacak K (Endocrine Reviews, doi: 10.1210/endrev/bnab019), the version originally published as Corrected Proof included inaccuracies resulting from transcription errors in some statistics reported in the text and in Table 6.
In the text, under the heading “Chemotherapy: cyclophosphamide/vincristine. Dacarbazine scheme and temozolamide,” in the sentence “Disease control rate with CVD chemotherapy was between 48% and 83%, and progression-free survival (PFS) was between 20 and 40 months in all studies,” “83%” is corrected to “100%” and “in all studies.” is deleted.
Under the heading “Radionuclide therapy,” in the sentence “There are several small, nonrandomized retrospective clinical studies (and one prospective study) suggesting that PRRT is one of the most effective (although not currently officially approved) clinical therapy approaches used for metastatic PPGLs, especially for PGLs associated with cluster 1 SDHx mutations,” “and one prospective study” is corrected to “and few prospective studies.”
In the sentence “This indicates a particularly high therapeutic potential of PRRT for SDHx related PGLs: The only prospective phase 2 PRRT study (nonrandomized) including 39 patients (all progressive at baseline) who received [90Y]DOTATOC reported an overall response rate of 47% (all PPGLs) and a remarkably long OS of 82 months for the subgroup of PGLs (n = 28),” “The only prospective” is corrected to “A prospective,” and “47%” is corrected to “18%.”
In the sentence “The disease control rate for PPGLs with PRRT was in most retrospective studies (10/13) ≥80% (67%-100%) and PFS was 13 to 38.5 months,” “(10/13)” is corrected to “(10/12).” “PFS was 13 to 38.5 months” is corrected to “PFS was 17 to 39 months.”
In the sentence “In a recently published meta-analysis of 179 pooled PPGL patients treated with PRRT (177Lu/90Y), a high disease control rate of 90% was reported,” “N=179” is corrected to “n=234.”
Under the heading “Tyrosine Kinase Inhibitors,” in the sentence “Nevertheless, in one retrospective study investigating sunitinib in PPGLs, 6/8 (75%) of the patients showing stable disease or a partial response were SDHB mutation carriers,” “6/8 (75%)” is corrected to “5/8 (62.5%).”
The lines from Table 6 reproduced below are corrected as marked:
| Author | Therapy | Patient number (n) | Complete response | Partial response | Stable disease | Median overall survival (OS)/ progression free survival (PFS)/time to progression (TTP) |
|---|---|---|---|---|---|---|
| Tanabe et al., 2013 | CVD chemotherapy | N=17 | 0% | 47.1%1 | 23.5% | PFS responders 40 months |
| Huang et al., 2008 | CVD chemotherapy* | N=18 (n=8 with SDHB orSDHDmutation) | 11% | 44% | OS responders/non-responders 3.8/1.8 years | |
| Averbuch et al., 1988 | CVD chemotherapy* | N=14 | 57% (complete plus partial response) | PFS 21 months (7 to >34 months) | ||
| Jawed et al., 2018 | Prolonged CVD chemotherapy (median 20,5 cycles) | N=12 (all with SDHBmutations) | 16,7% (2/12) | 66,7% (8/12) | 0%2 | OS/PFS 3.3/2.6 years |
| Ayala-Ramirez et al., 2012 | different chemotherapy regimens | N=54 (n=52 evaluable) (all progressive disease at baseline) | 33%3 | OS responders/non-responders 6.4/3.7 years | ||
| Hadoux et al. | Temozolomide monotherapy | N=15 (n=10 with SDHBmutations) | 0% | 33%4 | 47%4 | PFS 13.3 months |
| Nastos et al., 2017 | [131I]-MIBG vs. [177Lu]/ [90Y]DOTATATE(PRRT) | N=22 Patients (n=11 MIBG, n=9 [177Lu]DOTATATE, n=2 combinations, n=15 PGL, n=7 PCC) (all progressive disease at baseline) | MIBG: 63% vs. [177Lu]DOTATATE100% | OS/PFS MIBG 41.2/20.6 months vs. OS/PFS [177Lu]DOTATATE 60.8/38.5 months Sub-group PGLs: OS/PFS MIBG 22.8/14.4 months vs. OS/PFS [177Lu]DOTATATE 60.8/38.5 months (p<0,05) |
||
| Van Essen et al., 2006 | [177Lu] DOTATATE | N=12 (n=1 PCC, n=5 HN, n=6 other PGLs) | 0% | 16.7%5 | 50%5 | TTP 11 and 5 months, respectively in 2 patients, median TTP to progression not reached in PGL patients |
| Forrer et al., 2008 | [90Y] DOTATOC, 3 combined with [177Lu] DOTATATE | N=28 (n=9 PCC, n=19 PGL) (all progressive disease at baseline) | 0% | 25%1 | 46.4% | TTP 3 to > 42 months, median TTP 18±14 (6-44) months |
| Kong et al., 2017 | [177Lu] DOTATATE, 9 combined with radiosensitizing chemotherapy | N=20 (n=8 PCC, n=5 HN PGLs, n=5 abd. PGLs, n=2 HN plus abd. PGLs) (n=7 SDHB, n=1 SDHD, n=2 no mutation, n=10 unknown) | 0% | 36%1 | 50% | PFS 39 months, OS not reached |
| Puranik et al., 2015 | [90Y] DOTATOC n=4 combined with 177[Lu]-DOTATATE* | N=9 HN PGLs | 0% | 0% | 100% | - |
| Yadav et al., 2019 | 177[Lu]-DOTATATE | N=25 PGLs | 0% | 56% 28% | 28% 56% | PFS 32 months, OS not reached |
| Imhof et al. 2011 | [90Y] DOTATOC (phase II, prospective) | N=39 (n=11 PCCs, n=28 PGLs) (all progressive disease at baseline) | ns | 47% 18% | ns | Mean OS in PCC/PGL 32/82 months |
| Zandee et al., 2019 | 177[Lu]-DOTATATE | N=30 (n=17 parasympathetic PGLs, n=10 sympathetic PGLs, n=3 PCCs) | 0% | 23% | 67% | **PFS in PGL#/PCC 13/10 months, respectively |
| Satapathy et al., 2019 | 177[Lu]/[90Y] -DOTATATE, [90Y] DOTATOC | Meta-analysis from 12 studies: n= 201 | 0% | 25%6 | 59%6 | - |
| Taieb et al., 2019 | [90Y]/ 177[Lu]-DOTATATE | Meta-analysis n= 179 (n=234) | 90% (partial response plus stable disease) | |||
| Ayala-Ramirez et al., 2012 | TKI sunitinib(retrospective) | N=17 (n=14evaluable) | 0% | 21%(3/14) | 36%(5/14) | PFS 4.1 months (75% (6/8)62.5% (5/8)with stable disease or partial responseSDHBmutation carriers) |
| Jasim et al., 2017 | TKI pazopanib* | N=7 (6 evaluable) | 17% | PFS/OS 6.5/14.8 months | ||
| Oh et al., 2012 | MTORC1 inhibitor everolimus (phase II, prospective) | N=7 | 0% | 0% | 71% (5/7) |
Not assessed
PFS 3.8 months |
Added to caption: Minor response: any shrinkage of tumor which does not fulfill the criteria of partial response. If not indicated otherwise, reported minor/minimal response is included in “Stable disease.” The following footnotes were added:
1 Minor/minimal response included
2 Minor/minimal response excluded (2/12)
3 Overall response rate
4 According to RECIST plus PERCIST
5 Including all 12 patients of which only 11 were evaluable
6 This meta-analysis provides an overall response rate of 25% (n=179) and a disease control rate of 84% (n=151)
* prospective
**Overall PFS 30 months, parasympathetic PGL 91 months
# sympathetic
Text marked with strikethrough was deleted, and text underlined was added.
The corrections have been incorporated into the article online.